The Liver Meeting is being held in
San Francisco, starting on Nov. 4. In advance of this meeting, practice guidelines for the tx of Hep C Geno 1 have been published in the October issue of the journal Hepatology. This is a great article which compares and contrasts results of the clinical trials with both Boceprevir (VIC) and Telaprevir (INC), and addresses adverse events, lead-in, gene testing, etc. Happy reading!